DSNKY Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 22:59):

Stats
Šios dienos apimtis	130 983
Vidutinė apimtis	178 824
Rinkos kapitalizacija	68.03B
EPS	$20.84 ( 2023-09-30 )
Kita pelno data	( $0 ) 2024-07-29
Last Dividend	$0.119 ( 2021-09-28 )
Next Dividend	$0 ( N/A )
P/E	52.96
ATR14	$0.0110 (0.03%)

Tūris Koreliacija

Ilgas: 0.03 (neutral)

Trumpas: -0.12 (neutral)

Signal:(60.655) Neutral

Daiichi Sankyo Company, Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Daiichi Sankyo Company, Koreliacija - Valiuta/Žaliavos

0.06
( neutral )

0.25
( neutral )

-0.44
( neutral )

0.01
( neutral )

0.35
( neutral )

-0.24
( neutral )

Daiichi Sankyo Company, Finansinės ataskaitos

Annual	2024
Pajamos:	$1 601.69B
Bruto pelnas:	$1 186.37B (74.07 %)
EPS:	$104.69

FY	2024
Pajamos:	$1 601.69B
Bruto pelnas:	$1 186.37B (74.07 %)
EPS:	$104.69

FY	2023
Pajamos:	$1 278.48B
Bruto pelnas:	$914.95B (71.57 %)
EPS:	$56.96

FY	2022
Pajamos:	$1 044.89B
Bruto pelnas:	$691.56B (66.19 %)
EPS:	$34.94

Financial Reports:

No articles found.

Daiichi Sankyo Company, Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Daiichi Sankyo Company, Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 5.32 - Stable (6.44%)

Information

First Dividend	$0.122	2021-03-29
Last Dividend	$0.119	2021-09-28
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	2	--
Total Paid Out	$0.241	--
Avg. Dividend % Per Year	0.00%	--
Score	3.68	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	5.32
Div. Directional Score	8.87	--

Next Divdend (Est)
(2024-06-21)

$0 Estimate 0.00 %

Dividend Stability

0.04 Very Bad

Dividend Score

3.68

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for OTC

Symbol	Title	Last dividend	Frequency	Yearly Dividend
SGPYY	Ex Dividend Knight	2023-06-01	Semi-Annually	0.00%
GBLBY	Ex Dividend Junior	2023-05-11	Annually	0.00%
AGESY	Ex Dividend Junior	2023-10-25	Annually	0.00%
MYBF	Ex Dividend Knight	2023-10-04	Quarterly	0.00%
CNPWM	Ex Dividend Knight	2023-07-07	Quarterly	0.00%
SZLMY	Ex Dividend Junior	2023-05-03	Annually	0.00%
HNFSA	Ex Dividend Junior	2023-08-09	Quarterly	0.00%
ASBFY	Ex Dividend Knight	2023-06-01	Annually	0.00%
OTGLY	Ex Dividend Junior	2023-06-12	Annually	0.00%
DKILF	Ex Dividend Knight	2023-09-28	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.125	1.500	7.49	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0580	1.200	8.07	9.68	[0 - 0.3]
returnOnEquityTTM	0.125	1.500	9.72	10.00	[0.1 - 1]
payoutRatioTTM	0.335	-1.000	6.65	-6.65	[0 - 1]
currentRatioTTM	3.01	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	1.522	0.800	5.75	4.60	[0.8 - 2.5]
cashRatioTTM	0.895	1.500	6.14	9.21	[0.2 - 2]
debtRatioTTM	0.0294	-1.500	9.51	-10.00	[0 - 0.6]
interestCoverageTTM	11.63	1.000	6.80	6.80	[3 - 30]
operatingCashFlowPerShareTTM	312.54	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	248.50	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.0603	-1.500	9.76	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.741	1.000	0.988	0.988	[0.2 - 0.8]
operatingProfitMarginTTM	0.132	1.000	9.36	9.36	[0.1 - 0.6]
cashFlowToDebtRatioTTM	5.89	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.463	0.800	-0.248	-0.199	[0.5 - 2]
Total Score				12.41

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	50.01	1.000	5.05	0	[1 - 100]
returnOnEquityTTM	0.125	2.50	9.82	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	248.50	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	0.00172	1.500	9.96	0	[0 - 0.4]
operatingCashFlowPerShareTTM	312.54	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0.335	1.500	6.65	-6.65	[0 - 1]
pegRatioTTM	0.00509	1.500	-3.30	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.374	1.000	3.15	0	[0.1 - 0.5]
Total Score				5.32

Daiichi Sankyo Company,

Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.